Atria Investments Inc Sells 20,550 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Atria Investments Inc decreased its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 47.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,633 shares of the biopharmaceutical company's stock after selling 20,550 shares during the quarter. Atria Investments Inc's holdings in Royalty Pharma were worth $577,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Keene & Associates Inc. grew its holdings in shares of Royalty Pharma by 1.9% during the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock valued at $495,000 after buying an additional 370 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 376 shares in the last quarter. Sanctuary Advisors LLC grew its holdings in shares of Royalty Pharma by 0.9% during the fourth quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock valued at $1,068,000 after buying an additional 388 shares in the last quarter. Aurora Investment Counsel grew its holdings in shares of Royalty Pharma by 1.0% during the third quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company's stock valued at $1,427,000 after buying an additional 512 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Royalty Pharma by 31.4% during the fourth quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 590 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Remove Ads

Royalty Pharma Stock Up 1.2 %

Shares of NASDAQ:RPRX traded up $0.39 on Tuesday, reaching $33.41. The company had a trading volume of 2,714,300 shares, compared to its average volume of 2,824,295. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20. The stock has a 50-day moving average price of $31.73 and a 200 day moving average price of $28.59. The stock has a market capitalization of $19.26 billion, a P/E ratio of 23.04, a P/E/G ratio of 2.31 and a beta of 0.47. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, equities analysts expect that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.63%. The ex-dividend date was Friday, February 21st. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. Royalty Pharma's payout ratio is currently 60.69%.

Analyst Ratings Changes

Separately, TD Cowen raised Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.